HIV/AIDS Update - Changes to the Edurant (rilpivirine) label: drug-drug interaction update

["U.S. Food & Drug Administration (FDA)" <fda@xxxxxxxxxxxxxxxxxxxxxxx>]

Title: HIV/AIDS Update - Changes to the Edurant (rilpivirine) label: drug-drug interaction update

You are receiving this message as a subscriber to the FDA HIV/AIDS electronic list serve. The purpose of the list serve is to relay important information about HIV/AIDS-related products and issues, including product approvals, significant labeling changes, safety warnings, notices of upcoming public meetings and alerts to proposed regulatory guidances for comment.

Please do not reply to this message.

On May 1, 2014, FDA  approved changes to the Edurant (rilpivirine) label to include drug-drug interaction with rilpivirine and metformin, and rilpivirine and rifabutin.

 

Under section 2 Dosage and Administration:
Rifabutin Co-administration: For patients concomitantly receiving rifabutin, the EDURANT dose should be increased to 50 mg (two tablets of 25 mg each) once daily, taken with a meal.  When rifabutin co‑administration is stopped, the EDURANT dose should be decreased to 25 mg once daily, taken with a meal.

 

Rilpivirine did not have a clinically significant effect on the pharmacokinetics of metformin.

 

The complete revised label is available at Drugs@FDA .

 

Edurant is a member of the Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI) class of antiretroviral drugs, marketed by Tibotec Therapeutics.

 

Richard Klein
Office of Health and Constituent Affairs
Food and Drug Administration

Kimberly Struble
Division of Antiviral Products
Food and Drug Administration

Steve Morin
Office of Health and Constituent Affairs
Food and Drug Administration

Use the Clinical Guidelines Portal at AIDSinfo to find the most current version of the Adult and Adolescent ARV Guidelines, Adult and Adolescent OI Prevention and Treatment Guidelines, Perinatal Guidelines, Pediatric ARV Guidelines, Pediatric OI Prevention and Treatment Guidelines, Guidelines on Care for HIV-Infected Residents Displaced from Disaster Areas, Preexposure Prophylaxis (PrEP) Guidelines, Nonoccupational Postexposure Prophylaxis (nPEP) Guidelines, Recommendations for Hormonal Contraception, HIV Counseling, Testing, and Referral Guidelines, and Guidelines on Incorporating HIV Prevention in to Medical Care.

---

This email was sent to list-fda@xxxxxxxxxxx using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420